Rosiglitazone protects neuroblastoma cells against advanced glycation end products-induced injury

Acta Pharmacologica Sinica

Volumn 32, Issue 8, 2011, Pages 991-998

  Wang, Li ^a   Yu, Chun Jiang ^a   Liu, Wei ^b   Cheng, Lu Yang ^a   Zhang, Yi Na ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b Haidian Hospital   (China)

Author keywords

amyloid; advanced glycation end products; Alzheimer's disease; apoptosis; PPAR ; rosiglitazone; SH SY5Y cells

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADVANCED GLYCATION END PRODUCT; AMYLOID PRECURSOR PROTEIN; BETA ACTIN; BETA SECRETASE; BETA SECRETASE 1; CASPASE 3; CATALASE; DICHLORODIHYDROFLUORESCEIN DIACETATE; INSULINASE; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BRAIN INJURY; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL SURVIVAL; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; NEUROBLASTOMA; NEURONS; NEUROPROTECTIVE AGENTS; THIAZOLIDINEDIONES;

EID: 80051514413     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.81     Document Type: Article

References (31)

1. Guglielmotto M, Aragno M, Tamagno E, Vercellinatto I, Visentin S, Medana C, et al. AGEs/RAGE complex upregulates BACE1 via NFkappaB pathway activation. Neurobiol Aging 2010. doi: 10.1016/ j.neurobiolaging.2010.05.026
2. McCall AL. The impact of diabetes on the CNS. Diabetes 1992; 41: 557-70.
3. Wang SH, Sun ZL, Guo YJ, Yuan Y, Li L. PPAR?-mediated advanced glycation end products regulation of neural stem cells. Mol Cell Endocrinol 2009; 307: 176-84.
4. Munch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, et al. Alzheimer's disease - synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 1998; 105: 439-61. (Pubitemid 28365028)
5. Mruthinti S, Sood A, Humphrey CL, Swamy-Mruthinti S, Buccafusco JJ. The induction of surface beta-amyloid binding proteins and enhanced cytotoxicity in cultured PC-12 and IMR-32 cells by advanced glycation end products. Neuroscience 2006; 142: 463-73. (Pubitemid 44415326)
6. Woltjer RL, Maezawa I, Ou JJ, Montine KS, Montine TJ. Advanced glycation endproduct precursor alters intracellular amyloid-beta/ A beta PP carboxy-terminal fragment aggregation and cytotoxicity. J Alzheimers Dis 2003; 5: 467-76. (Pubitemid 38101235)
7. Loske C, Neumann A, Cunningham AM, Nichol K, Schinzel R, Riederer P, et al. Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress. J Neural Transm 1998; 105: 1005-15. (Pubitemid 28539843)
8. Gasic-Milenkovic J, Loske C, Deuther-Conrad W, Munch G. Protein "AGEing" - cytotoxicity of a glycated protein increases with its degree of AGE-modification. Z Gerontol Geriatr 2001; 34: 457-60. (Pubitemid 34087418)
9. Deuther-Conrad W, Loske C, Schinzel R, Dringen R, Riederer P, Munch G. Advanced glycation endproducts change glutathione redox status in SH-SY5Y human neuroblastoma cells by a hydrogen peroxide dependent mechanism. Neurosci Lett 2001; 312: 29-32. (Pubitemid 32907545)
10. Wei Y, Chen L, Chen J, Ge L, He RQ. Rapid glycation with D-ribose induces globular amyloid-like aggregations of BSA with high cytotoxicity to SH-SY5Y cells. BMC Cell Biol 2009; 10: 10.
11. Kuhla B, Loske C, Garcia De Arriba S, Schinzel R, Huber J, Munch G. Differential effects of "Advanced glycation endproducts" and betaamyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y. J Neural Transm 2004; 111: 427-39. (Pubitemid 38316614)
12. de Arriba SG, Stuchbury G, Yarin J, Burnell J, Loske C, Munch G. Methylglyoxal impairs glucose metabolism and leads to energy depletion in neuronal cells - protection by carbonyl scavengers. Neurobiol Aging 2007; 28: 1044-50. (Pubitemid 46635909)
13. Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 2001; 81: 741-66. (Pubitemid 32267077)
14. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-18.
15. Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fujii N, et al. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol 1998; 153: 1149-55. (Pubitemid 28465838)
16. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-8.
17. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci U S A 1992; 89: 2873-7.
18. Pugliese G, Pricci F, Romeo G, Pugliese F, Mene P, Giannini S, et al. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 1997; 46: 1881-7. (Pubitemid 27456425)
19. Takeuchi M, Kikuchi S, Sasaki N, Suzuki T, Watai T, Iwaki M, et al. Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. Curr Alzheimer Res 2004; 1: 39-46.
20. Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2006; 21: 197-208. (Pubitemid 44051058)
21. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overxepression in proximal tubular cells. Kidney Int 2003; 63; 464-73. (Pubitemid 36126793)
22. Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, Fantozzi R. PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int 2009; 55: 496-504.
23. Jung TW, Lee JY, Shim WS, Kang ES, Kim SK, Ahn CW, et al. Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production. J Neurol Sci 2007; 253: 53-60. (Pubitemid 46185454)
24. Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008; 5: 481-9. (Pubitemid 351952487)
25. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004; 27: 484-90. (Pubitemid 38174076)
26. Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez G, et al. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem 2007; 282: 37006-15.
27. Wang YL, Frauwirth KA, Rangwala SM, Lazar MA, Thompson CB. Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. J Biol Chem 2002; 277: 31781-8. (Pubitemid 34968983)
28. Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 2004; 24: 10908-17. (Pubitemid 39602402)
29. d'Abramo C, Massone S, Zingg JM, Pizzuti A, Marambaud P, Dalla Piccola B, et al. Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid betamediated cell death. Biochem J 2005; 391: 693-8. (Pubitemid 41634796)
30. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 2003; 23: 9796-804. (Pubitemid 37371592)
31. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 2003; 162: 313-9. (Pubitemid 36042013)